CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2017		Jun. 30, 2016
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (53,123)		$ (502,065)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	38,497		47,383
Non-cash interest expense	15,601		14,762
Accretion of discount on investments	1,327		536
Stock-based compensation	70,775		64,075
Gain on the sale of equity investments	(3,252)		2,027
Impairment of intangible assets	0		599,118
Deferred income taxes	(22,770)		(191,131)
Unrealized foreign exchange gain on forward contracts	(4,870)		(7,882)
Non-cash changes in the fair value of contingent acquisition consideration payable	7,195		(59,066)
Other	3,806		705
Changes in operating assets and liabilities:
Accounts receivable, net	(16,834)		(50,250)
Inventory	(60,369)		(41,600)
Other current assets	(3,710)		3,186
Other assets	(1,109)		(1,439)
Accounts payable and accrued liabilities	(36,286)		(87,560)
Other long-term liabilities	3,459		(8,058)
Net cash used in operating activities	(61,663)		(217,259)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property, plant and equipment	(116,847)		(70,710)
Maturities and sales of investments	234,617		283,780
Purchase of available-for-sale securities	(130,986)		(58,914)
Business acquisitions, net of cash acquired	0		(1,467)
Other	(1,560)		(150)
Net cash (used in) provided by investing activities	(14,776)		152,539
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from exercises of stock options and the ESPP	40,659		23,014
Taxes paid related to net share settlement of equity awards	(26,624)		(52,824)
Payment of contingent acquisition consideration payable	(1,894)		0
Other	(28)		0
Net cash provided by (used in) financing activities	12,113		(29,810)
Effect of exchange rate changes on cash	10,860		3,459
NET DECREASE IN CASH AND CASH EQUIVALENTS	(53,466)		(91,071)
Cash and cash equivalents:
Beginning of period	408,330	[1]	397,040
End of period	354,864		305,969
SUPPLEMENTAL CASH FLOW DISCLOSURES:
Cash paid for interest, net of interest capitalized into fixed assets	4,519		4,521
Cash paid for income taxes	16,341		93,969
Stock-based compensation capitalized into inventory	7,600		5,751
Depreciation capitalized into inventory	11,752		8,993
SUPPLEMENTAL CASH FLOW DISCLOSURES FOR NON CASH INVESTING AND FINANCING ACTIVITIES:
Decrease in accounts payable and accrued liabilities related to fixed assets	(29,300)		(17,130)
Conversion of convertible debt	22,477		6,941
Accrual for inventory purchases related to the acquisition of the Merck PKU Business	$ 0		$ 1,322

[1] December 31, 2016 balances were derived from the audited Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016, filed with the Securities and Exchange Commission (the SEC) on February 27, 2017.